Transplantation of the Lung

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Eur Respir J REVIEW 1990, 3 , 594-605 Transplantation of the lung T. Higenbottam, B.A. Otulana, J. Wallwork Transplantation of the lung. T . Higenbottam, BA. Otulana, J. Wallwork. Dept of Respiratory Physiology, Papworth Hospital, ABSTRACT: The Introduction of cyclosporlne as a highly effective Papwonh Everard, Cambridge CB3 8RE, UK. Immunosuppressive agent and the development of new techniques for heart­ lung and lung transplantation have led to a new treatment for a wide Correspondence: Dr T. Higenbottam, Dept of range of fatal cardiopulmonary diseases. Indications for surgery are now Respiratory Physiology, Papwonh Hospital, Papwonh Everard, Cambridge CB3 8RE, UK. becoming clear, together with major contra-indications. Suppurative lung disease, such as cystic fibrosis, can be effectively treated by heart-lung Keywords: Lung transplantation, heart-lung transplan­ transplant (HLT). A whole new field or pulmonary medJcine is emerging tation, lung rejection, obliterative bronchiolitis. to provide the physiological monitoring and diagnostic techniques for major complications such as opportunistic lung Infection and pulmonary Received: August, 1989; accepted after revision rejection. Obllteratlve bronchiolitis, a consequence of frequent and severe November 30, 1989. rejection, stlU provides a major challenge to the immunological scientist and respiratory physician. Lung transplantation, by disrupting the vascu­ lar supply and innervation of the lung, Is raising major questions about the generally accepted beliefs of regulation of breathing and pulmonary mechanics. Finally, as the survival rate improves beyond the current SO% at 3 yrs, lung transplantation will perhaps present further challenges to our understanding of the pathogenesls of various diseases such as asthma and cystic fibrosis. Eur Respir 1., 1990, 3, 594-605. Tbe surgical techniques long-tenn survival. The healing of the tracheal anasto­ mosis, with the "en bloc" technique, is aided by With the clinical success of renal and cardiac collateral blood supply arising from the mcdiatinum, transplantation tremendous interest developed in the principally the coronary arteries which supply the lower possibility of lung and heart-lung transplantation for trachea and carina [9]. end-stage cardiopulmonary and lung disease. Early Widespread use of HLT is limited by availability of animal studies confirmed the technical feasibility of lung suitable donors, particularly as cardiac transplantation is transplantation, but concern remained about long-tenn so successful [10]. Single lung transplantation offers a survival, particularly in the absence of vagal innervation solution by enabling lungs and heart to be used for of the lung [1]. Non-primate mammals appear unable to separate recipients. The introduction of the "omental sustain ventilation without pulmonary vagal innervation wrap" [11) mobilizing the omentum and wrapping it but, fortunately, primates [2] including man sustain around the bronchial anastomosis has contributed to nonnal ventilation despite loss of pulmonary vagal clinically successful single lung transplantation [12]. innervation [3]. Double lung transplantation, without the heart has also Early experience of clinical lung transplantation was been described [13] but tracheal anastomosis healing is not promising, long-tenn survivors being rare [4]. One poorer than in HLT presumably because of the loss of of the main problems encountered by early workers mediastinal collaterals. Alternatively bilateral bronchial involved the healing of the airway anastomosis [5]. Two anastomosis with "omental wraps" may offer a solution scientific developments, however, provided a solution. to enable double lung transplantation [14]. But as HLT In 1976, BoREL et al. discovered the powerful appears so successful, to enhance the availability of donor immunosuppressive, cyclosporine (previously called organs the "domino" operation has been devised where cyclosporin A) which inhibits T lymphocyte helper cells, the heart of the HLT recipient is donated to another probably by binding to a specific protein receptor, called cardiac recipient. cyclophilin [7]. High dose steroids could be avoided, particularly during the early post-operative period, by use of cyclosporine, with clear benefits to wound heal­ Medical after care ing. Using an earlier report of a similar surgical tech­ nique, REITZ et al. in Stanford [8] developed the "en Early experience of lung transplantation identified two bloc" heart-lung transplant (HL1) operation in a primate major problems in aftercare. The first was a high model in combination with cyclosporine to achieve incidence of primary graft failure, so called TRANSPLANTATION OF THE LUNG 595 post-implantation syndrome which closely resembles adult Table 1. - Causes of early surgical death in eight respiratory distress syndrome [15]. The second was the heart-lung transplant (HLT) recipients in the immediate inability to detect graft rejection and distinguish rejec­ post-operative period tion from pulmonary infection; lung rejection in a chronic Number of patients form contributing to long-term graft failure [16]. Cause of death Cerebrovascular event 2 Tracheal dehiscence 1 Preservation of the donor lung Inflated/ruptured aorta 1 Small bowel infarction/SLE 1 It is essential that after lung transplantation, the new ARDS/hepatic dysfunction 1 graft function immediately. There is no equivalent to Early graft failure 1 haemodialysis, which is used in renal transplantation to ensure the patient's survival until the graft begins to Total 7 out of 61 operations function. During the donor operation and with subse­ ARDS: adult respiratory distress syndrome. quent transportation to the recipient the lungs experience prolonged ischaemia. To reduce ischaemic injury solid organs are cooled [17]. Colloidal solutions seem beuer vehicles to cool the lungs than crystaloid solutions [18]. Table 2. - Criteria for donor selection Also, it is probably better to keep the lungs inflated than 1. Age below 40 yrs. deflated [19] in preserving function. Using these prin­ 2. No major thoracic trauma. ciples the early HL T surgery involved transporting the 3. No past history of pulmonary disease, including asthma. donor to the recipient hospital, the donor and recipient 4. A short period of ventilation. operations being performed in adjoining operating 5. No systemic or pulmonary infections. theatres to reduce to a minimum the ischaemic time. 6. Normal chest X-ray. Obvious practical and ethical problems ensued from 7. Normal lung compliance with peak inspiratory pressure moving donors, which limited availability, a method for <20 nunHg, tidal volume of <15 ml·kg·1 and respiratory 1 long-term preservation was therefore needed. rate 10-14 br·min· • 8. Normal gas exchange, arterial oxygen tension (Pao2) ) 300 • <15 kPa with fractional inspiratory oxygen (Fto2 30%. 9. Inotropic requirement <10 )J.g·kg"1·min·1 of dopamine or dobutamine. 10. Normal electrocardiogram (ECG). 250 vascular bed, before infusion of a single flush colloidal 200 based preservation solution [21, 22). This method • achieves ischaemic times up to 5.5 h and excellent <>I 0 :I: E immediate graft function (fig. 1}. Only one primary graft E failure occurred in 61 HLT patients where most were 150 • 8c extubated within 24 h of surgery (table 1). At present the ~ 0 main limit to the ischaemic time in HLT is probably the 0 '0= inability to preserve cardiac function. N 0 0 0... 100· 0 No matter how effective the long-term preservation c( system, careful selection of the donor organs is impor­ • tant (table 2) to lessen the risks of using injured or 50· damaged lungs and to avoid obviously infected organs. 0 Diagnosis of lung rejection After Pre- One week bypass extubation postoperatlvely Lung rejection was a major problem in the early ) Fig. I. - Alveolar·atterial oxygen gradient (A-ao2 for near and distant experience of transplantation. Repeated untreated acute procurement groups at various times post-operatively. rejection is now thought to have contributed to the dis­ abling and fatal airways obstruction seen in up to 50% Recently a number of methods have been described to of HLT patients [20, 23). With HLT it had been thought extend ischaemic times to enable procurement of organs that endomyocardial biopsy (EMB), a method established from distant hospitals. One such method involves a to diagnose rejection in cardiac transplantation [24], could mechanical system which perfuses the heat-lung block be used to monitor rejection. However, both experimen­ during transportation [20]. Another was using tal [25] and clinical [26) studies suggest that the lungs cardiopulmonary bypass to cool the lungs before har­ undergo rejection before the heart. Indeed we have now vesting. Perhaps the simplest method uses intravenous abandoned the use of EMB in HLT patients as cardiac prostacyclin (PGI2) to vasodilate the donor's pulmonary rejection is rare if the lung rejection is controlled [27]. 596 T. HIGENBOTTAM, B.A. OTID..ANA, J. WALLWORK Additionally, HLT patients commonly experience pul­ A monary infections [20]; the same is true for single lung transplant patients [12]. Transbronchial lung biopsy (TBB) through a 140 FEV1 fibreoptic bronchoscope provides a sensitive means for diagnosing lung rejection [28] anq enables distinction 120 from pulmonary infection [29]. The technique has now "0 been extended to child HLT patients [30]. G) With a clear hiStological diagnosis it has proved pos­ ..Q. 100 sibte to demonstrate the clinical featw:~
Recommended publications
  • Surgical Advances in Heart and Lung Transplantation

    Surgical Advances in Heart and Lung Transplantation

    Anesthesiology Clin N Am 22 (2004) 789–807 Surgical advances in heart and lung transplantation Eric E. Roselli, MD*, Nicholas G. Smedira, MD Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA The first heart transplants were performed in dogs by Alexis Carrel and Charles Guthrie in 1905, but it was not until the 1950s that attempts at human orthotopic heart transplant were reported. Several obstacles, including a clear definition of brain death, adequate organ preservation, control of rejection, and an easily reproducible method of implantation, slowed progress. Eventually, the first successful human to human orthotopic heart transplant was performed by Christian Barnard in South Africa in 1967 [1]. Poor healing of bronchial anastomoses hindered early progress in lung transplantation, first reported in 1963 [2]. The first successful transplant of heart and both lungs was accomplished at Stanford University School of Medicine (Stanford, CA) in 1981 [3]. The introduction of cyclosporine to immunosuppres- sion protocols, with lower doses of steroids, led to the first successful isolated lung transplant, performed at Toronto General Hospital in 1983 [4]. Since these early successes at thoracic transplantation, great progress has been made in the care of patients with end-stage heart and lung disease. Although only minor changes have occurred in surgical technique for heart and lung transplantation, the greatest changes have been in liberalizing donor criteria to expand the donor pool. This article focuses on more recent surgical advances in donor selection and management, procurement and implantation, and the impact these advances have had on patient outcome.
  • Clinical Policy: Lung Transplantation Reference Number: CP.MP.57 Coding Implications Last Review Date: 05/20 Revision Log

    Clinical Policy: Lung Transplantation Reference Number: CP.MP.57 Coding Implications Last Review Date: 05/20 Revision Log

    Clinical Policy: Lung Transplantation Reference Number: CP.MP.57 Coding Implications Last Review Date: 05/20 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Medical necessity criteria for the review of lung transplantation requests. Policy/Criteria I. It is the policy of health plans affiliated with Centene Corporation® that lung transplant for members with chronic, end-stage lung disease who have failed maximal medical therapy is medically necessary when all of the following criteria are met: A. High (> 50%) risk of death from lung disease within 2 years if lung transplantation is not performed. B. High (> 80%) likelihood of surviving at least 90 days after lung transplantation. C. High (> 80%) likelihood of 5-year post-transplant survival from a general medical perspective provided that there is adequate graft function. D. Does not have ANY of the following absolute contraindications: 1. Malignancy, except for non-melanoma localized skin cancer that has been treated appropriately, low grade prostate cancer, a malignancy that has been completely resected, or a treated malignancy determined to have a small likelihood of recurrence and acceptable future risks; 2. Untreatable significant dysfunction of another major organ system unless combined organ transplantation can be performed; 3. Uncorrected atherosclerotic disease with suspected or confirmed end-organ ischemia or dysfunction and/or coronary artery disease not amenable to revascularization; 4. Acute medical instability, including, but not limited to, acute sepsis, acute viral respiratory infection, myocardial infarction, and liver failure; 5. Uncorrectable bleeding diathesis; 6. Chronic infection with highly virulent and/or resistant microbes that are poorly controlled pre-transplant; 7.
  • Lung Transplantation with the OCS (Organ Care System)

    Lung Transplantation with the OCS (Organ Care System)

    Lung Transplantation with the OCSTM (Organ Care System) Lung System Bringing Breathing Lung Preservation to Transplant Patients A Guide for You and Your Family DRAFT ABOUT THIS BOOKLET This booklet was created for patients like you who have been diagnosed with end-stage lung failure and are candidates for a lung transplant. It contains information that will help you and your family learn about options available to you for a transplant. This booklet includes information on your lungs, how they function, and respiratory failure. In addition, you will learn about a new way to preserve lungs before transplantation, called breathing lung preservation. Your doctor is the best person to explain your treatment options and their risks and to help you decide which option is right for you. The booklet explains: • Breathing lung preservation with the OCS™ Lung System • How the OCS™ Lung System works • Who is eligible for the OCS™ Lung System • Lung transplant complications • How the lungs function • What is respiratory failure and the treatment options • What to expect during your treatment • Summary of clinical data for the OCS™ Lung System • Contact Information Please read this booklet carefully and share it with your family and caregivers. For your convenience, a glossary is provided in the front of this booklet. Terms in the text in bold italics are explained in the glossary. If you have questions about the OCS™ Lung System that are not answered in this booklet, please ask your physician. This booklet is intended for general information only. It is not intended to tell you everything you need to know about a lung transplant.
  • Chronic Lung Allograft Dysfunction Post Lung Transplantation: a Review of Computed Tomography Quantitative Methods for Detection and Follow-Up

    Chronic Lung Allograft Dysfunction Post Lung Transplantation: a Review of Computed Tomography Quantitative Methods for Detection and Follow-Up

    Journal of Clinical Medicine Review Chronic Lung Allograft Dysfunction Post Lung Transplantation: A Review of Computed Tomography Quantitative Methods for Detection and Follow-Up Trieu-Nghi Hoang-Thi 1,2,3 , Guillaume Chassagnon 1, Thong Hua-Huy 3, Veronique Boussaud 4, Anh-Tuan Dinh-Xuan 3 and Marie-Pierre Revel 1,* 1 AP-HP.Centre, Hôpital Cochin, Department of Radiology, Université de Paris, 75014 Paris, France; [email protected] (T.-N.H.-T.); [email protected] (G.C.) 2 Department of Diagnostic Imaging, Vinmec Central Park Hospital, Ho Chi Minh City 70000, Vietnam 3 AP-HP.Centre, Hôpital Cochin, Department of Respiratory Physiology, Université de Paris, 75014 Paris, France; [email protected] (T.H.-H.); [email protected] (A.-T.D.-X.) 4 AP-HP.Centre, Hôpital Cochin, Department of Pneumology, Université de Paris, 75014 Paris, France; [email protected] * Correspondence: [email protected]; Tel.: +33-1-5841-2471 Abstract: Chronic lung allograft dysfunction (CLAD) remains the leading cause of morbidity and mortality after lung transplantation. The term encompasses both obstructive and restrictive pheno- types, as well as mixed and undefined phenotypes. Imaging, in addition to pulmonary function tests, plays a major role in identifying the CLAD phenotype and is essential for follow-up after Citation: Hoang-Thi, T.-N.; lung transplantation. Quantitative imaging allows for the performing of reader-independent precise Chassagnon, G.; Hua-Huy, T.; Boussaud, V.; Dinh-Xuan, A.-T.; evaluation of CT examinations. In this review article, we will discuss the role of quantitative imaging Revel, M.-P.
  • Islet Interleukin-1Β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to Β-Cell Failure

    Islet Interleukin-1Β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to Β-Cell Failure

    Diabetes Care 1 Islet Interleukin-1b Rebecca L. Hull,1 Ronald L. Gibson,2 Sharon McNamara,2 Gail H. Deutsch,3 Immunoreactivity Is an Early Corinne L. Fligner,3 Charles W. Frevert,1,4 Bonnie W. Ramsey,2 and Srinath Sanda5,6 Feature of Cystic Fibrosis That May Contribute to b-Cell Failure https://doi.org/10.2337/dc17-1387 OBJECTIVE Cystic fibrosis–related diabetes (CFRD) is a common complication of cystic fibrosis (CF), increasing patient morbidity and mortality. Poor understanding of CFRD path- ogenesis limits the development of targeted therapies to treat and/or prevent the disease. The aim of this study was to evaluate islet pathology, specifically, inflam- mation, amyloid deposition, and endocrine cell composition in subjects with CF with diabetes and with CF without diabetes. RESEARCH DESIGN AND METHODS A retrospective analysis of archived pancreas tissue collected at autopsy was con- ducted using pancreas tissue from subjects with CF and diabetes (CFRD) (n = 18) and PATHOPHYSIOLOGY/COMPLICATIONS CF without diabetes (CF-no DM) (n = 17). Two cohorts of control non-CF subjects were identified, each matched to CFRD and CF-no DM subjects for age, sex, and BMI (non-CF older, n = 20, and non-CF younger, n = 20), respectively. Immunohistochem- istry was performed to assess IL-1b and islet hormone (insulin, glucagon, somato- statin, and pancreatic polypeptide) immunoreactivity; histochemistry was performed 1Department of Medicine, University of Wash- to quantify amyloid deposition. ington, Seattle, WA 2Department of Pediatrics, University of Wash- RESULTS ington, Seattle, WA 3Department of Pathology, University of Wash- Islet IL-1b immunoreactivity was substantially increased in both CFRD and CF-no DM ington, Seattle, WA subjects compared with non-CF subjects and was common in young subjects with CF 4Department of Comparative Medicine, Univer- (£10 years of age).
  • Airway Versus Transbronchial Biopsy and BAL in Lung Transplant Recipients: Different but Complementary

    Airway Versus Transbronchial Biopsy and BAL in Lung Transplant Recipients: Different but Complementary

    Eur Respir J 1997; 10: 2876–2880 Copyright ERS Journals Ltd 1997 DOI: 10.1183/09031936.97.10122876 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 Airway versus transbronchial biopsy and BAL in lung transplant recipients: different but complementary C. Ward, G.I. Snell, B. Orsida, L. Zheng, T.J. Williams, E.H. Walters Airway versus transbronchial biopsy and BAL in lung transplant recipients: different Dept of Respiratory Medicine, Alfred but complementary. C. Ward, G.I. Snell, B. Orsida, L. Zheng, T.J. Williams, E.H. Walters. Hospital and Monash University Medical ©ERS Journals Ltd 1997. School, Melbourne, Australia. ABSTRACT: Lung transplantation is now an established therapeutic intervention Correspondence: E.H Walters for end-stage cardiopulmonary disease in humans. Chronic rejection, in the form Dept of Respiratory Medicine of bronchiolitis obliterans syndrome (BOS), remains the commonest cause of mor- Alfred Hospital bidity and mortality in those surviving more than 3 months. The pathology of BOS Prahran involves airway changes. We have evaluated the potential for endobronchial biop- Melbourne sies (EBB) to complement existing sampling methods used in allograft monitoring Victoria 3181 and have compared the results of EBB findings with those of bronchoalveolar Australia lavage (BAL) and transbronchial biopsy (TBB) in 18 clinically stable patients. Keywords: Bronchoalveolar lavage We found that all the EBB had inflammatory cells present but that only five endobronchial biopsy TBB specimens had evidence of inflammation, with airway material being present lung transplant in 78% of the TBB. Paired BAL and EBB yielded different results, with no cor- transbronchial biopsy relations between total macrophages, lymphocytes, CD4+ cells or CD8+ cells.
  • Icd-9-Cm (2010)

    Icd-9-Cm (2010)

    ICD-9-CM (2010) PROCEDURE CODE LONG DESCRIPTION SHORT DESCRIPTION 0001 Therapeutic ultrasound of vessels of head and neck Ther ult head & neck ves 0002 Therapeutic ultrasound of heart Ther ultrasound of heart 0003 Therapeutic ultrasound of peripheral vascular vessels Ther ult peripheral ves 0009 Other therapeutic ultrasound Other therapeutic ultsnd 0010 Implantation of chemotherapeutic agent Implant chemothera agent 0011 Infusion of drotrecogin alfa (activated) Infus drotrecogin alfa 0012 Administration of inhaled nitric oxide Adm inhal nitric oxide 0013 Injection or infusion of nesiritide Inject/infus nesiritide 0014 Injection or infusion of oxazolidinone class of antibiotics Injection oxazolidinone 0015 High-dose infusion interleukin-2 [IL-2] High-dose infusion IL-2 0016 Pressurized treatment of venous bypass graft [conduit] with pharmaceutical substance Pressurized treat graft 0017 Infusion of vasopressor agent Infusion of vasopressor 0018 Infusion of immunosuppressive antibody therapy Infus immunosup antibody 0019 Disruption of blood brain barrier via infusion [BBBD] BBBD via infusion 0021 Intravascular imaging of extracranial cerebral vessels IVUS extracran cereb ves 0022 Intravascular imaging of intrathoracic vessels IVUS intrathoracic ves 0023 Intravascular imaging of peripheral vessels IVUS peripheral vessels 0024 Intravascular imaging of coronary vessels IVUS coronary vessels 0025 Intravascular imaging of renal vessels IVUS renal vessels 0028 Intravascular imaging, other specified vessel(s) Intravascul imaging NEC 0029 Intravascular
  • FY 2009 Final Addenda ICD-9-CM Volume 3, Procedures Effective October 1, 2008

    FY 2009 Final Addenda ICD-9-CM Volume 3, Procedures Effective October 1, 2008

    FY 2009 Final Addenda ICD-9-CM Volume 3, Procedures Effective October 1, 2008 Tabular 00.3 Computer assisted surgery [CAS] Add inclusion term That without the use of robotic(s) technology Add exclusion term Excludes: robotic assisted procedures (17.41-17.49) New code 00.49 SuperSaturated oxygen therapy Aqueous oxygen (AO) therapy SSO2 SuperOxygenation infusion therapy Code also any: injection or infusion of thrombolytic agent (99.10) insertion of coronary artery stent(s) (36.06-36.07) intracoronary artery thrombolytic infusion (36.04) number of vascular stents inserted (00.45-00.48) number of vessels treated (00.40-00.43) open chest coronary artery angioplasty (36.03) other removal of coronary obstruction (36.09) percutaneous transluminal coronary angioplasty [PTCA] (00.66) procedure on vessel bifurcation (00.44) Excludes: other oxygen enrichment (93.96) other perfusion (39.97) New Code 00.58 Insertion of intra-aneurysm sac pressure monitoring device (intraoperative) Insertion of pressure sensor during endovascular repair of abdominal or thoracic aortic aneurysm(s) New code 00.59 Intravascular pressure measurement of coronary arteries Includes: fractional flow reserve (FFR) Code also any synchronous diagnostic or therapeutic procedures Excludes: intravascular pressure measurement of intrathoracic arteries (00.67) 00.66 Percutaneous transluminal coronary angioplasty [PTCA] or coronary atherectomy Add code also note Code also any: SuperSaturated oxygen therapy (00.49) 1 New code 00.67 Intravascular pressure measurement of intrathoracic
  • What Is Lung Transplantation?

    What Is Lung Transplantation?

    American Thoracic Society PATIENT EDUCATION | INFORMATION SERIES What is Lung Transplantation? Lung transplants are performed as a life saving treatment for people with end-stage lung disease. A lung transplant is a surgery to remove diseased lungs and replace them with lungs from a deceased donor with healthy lungs. There are only a few specialized centers around the world where lung transplants are performed. You will need to be referred to one of these centers to be considered for the surgery. Do I need a lung transplant? oxygen requirement, pulmonary function test results, distance Lung transplantation is an option for people with ‘end walked in 6 minutes and the type of lung disease you have. stage’ lung diseases such as chronic obstructive pulmonary Your transplant team may update your score over time if some disease (COPD), pulmonary fibrosis, cystic fibrosis (CF), of these factors change. pulmonary arterial hypertension (PAH), sarcoidosis, and Other factors used when matching donor lungs to a transplant other more rare lung diseases (See “Recipient Selection for recipient include: Lung Transplantation”). Lung transplantation should only be considered when you and your physician have exhausted all ■ where the donor is, other forms of available treatment. However, lung transplant ■ donor and recipient blood types, should be performed before you become too sick to tolerate the ■ surgery. Hence, the timing of evaluation and the surgery itself is antibodies you may have against certain donors’ blood very important. and tissues, ■ In order to qualify for surgery, you need to be evaluated at a donor lung size and your chest size (often related to lung transplant center.
  • Heart, Lung, and Heart-Lung Transplantation

    Heart, Lung, and Heart-Lung Transplantation

    Medical Coverage Policy Effective Date ............................................. 9/15/2021 Next Review Date ....................................... 9/15/2022 Coverage Policy Number .................................. 0129 Heart, Lung, and Heart-Lung Transplantation Table of Contents Related Coverage Resources Overview .............................................................. 1 Ventricular Assist Devices (VADs), Percutaneous Coverage Policy ................................................... 1 Cardiac Support Systems and Total Artificial General Background ............................................ 3 Heart Medicare Coverage Determinations .................. 16 Transplantation Donor Charges Coding/Billing Information .................................. 16 Laboratory Testing for Transplantation Rejection Extracorporeal Photopheresis References ........................................................ 17 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary
  • Transplant Recipient Outcome in the Lung Allocation Score Era in Eurotransplant – a Historical Prospective Study

    Transplant Recipient Outcome in the Lung Allocation Score Era in Eurotransplant – a Historical Prospective Study

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Erasmus University Digital Repository Transplant International ORIGINAL ARTICLE Impact of donor lung quality on post-transplant recipient outcome in the Lung Allocation Score era in Eurotransplant – a historical prospective study Jacqueline M. Smits1 , Jens Gottlieb2,3, Erik Verschuuren4, Patrick Evrard5, Rogier Hoek6, Christiane Knoop7,Gyorgy€ Lang8, Johanna M. Kwakkel-van Erp9, Robin Vos10 , Geert Verleden10, Benoit Rondelet11, Daniel Hoefer12, Frank Langer13, Rene Schramm14, Konrad Hoetzenecker8, Diana van Kessel15, Bart Luijk16, Leonard Seghers6, Tobias Deuse17, Roland Buhl18, Christian Witt19, Agita Strelniece1, Dave Green1, Erwin de Vries1, Guenter Laufer20 & Dirk Van Raemdonck21 1 Eurotransplant International Foundation, Leiden, The Netherlands SUMMARY 2 Department of Respiratory The aim of this study was to investigate whether there is an impact of Medicine, Hannover Medical School, donation rates on the quality of lungs used for transplantation and Hannover, Germany whether donor lung quality affects post-transplant outcome in the current 3 Biomedical Research in End-stage Lung Allocation Score era. All consecutive adult LTx performed in Euro- and Obstructive Disease (Breath), transplant (ET) between January 2012 and December 2016 were included German Centre for Lung Research = (DZL), Hannover, Germany (N 3053). Donors used for LTx in countries with high donation rate were younger (42% vs. 33% ≤45 years, P < 0.0001), were less often smok- 4 Department of Pulmonary < Medicine and Tuberculosis, ers (35% vs. 46%, P 0.0001), had more often clear chest X-rays (82% vs. University Medical Center 72%, P < 0.0001), had better donor oxygenation ratios (20% vs.
  • Annual Report 20 14 Eurotransplant International Foundation

    Annual Report 20 14 Eurotransplant International Foundation

    Annual Report 20 14 Eurotransplant International Foundation Edited by Undine Samuel Central office P.O. box 2304 2301 CH Leiden The Netherlands Tel. +31-71-579 57 00 Fax. +31-71-579 00 57 www.eurotransplant.org twitter.com/eurotransplant All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying or elswise, without prior permission. Eurotransplant | Annual Report 2014 1 CIP-GEGEVENS KONINKLIJKE BIBLIOTHEEK, DEN HAAG Annual Report/Eurotransplant International Foundation.–Leiden: Eurotransplant Foundation. -III., graf., tab. Published annually Annual report 2014 / ed. by Undine Samuel ISBN-EAN: 978-90-71658-33-4 Keyword: Eurotransplant Foundation; annual reports. 2 Eurotransplant | Annual Report 2014 Table of contents Foreword 5 1. Basic principles of the Eurotransplant community 9 2. Report of the Board and the central office 17 3. Transplant programs and their delegates in 2014 33 4. Eurotransplant: donation, waiting lists and transplants 41 5. Kidney: donation, waiting lists and transplants 65 6. Thoracic organs: donation, waiting lists and transplants 85 7. Liver and Intestine: donation, waiting lists and transplants 107 8. Pancreas and Islets: donation, waiting lists and transplants 121 9. Agreements between transplant programs within and outside Eurotransplant 135 10. Reporting of non-resident transplants in Eurotransplant 139 11. Histocompatibility Testing 141 12. Scientific Output in 2014 147 13. Eurotransplant personnel related statistics 151 14. Abbreviated financial statements 153 List of abbreviations 159 Eurotransplant | Annual Report 2014 3 4 Eurotransplant | Annual Report 2014 Foreword In 2014, Eurotransplant (ET) allocated 7.183 deceased donor organs from 2.041 donors to patients on the waiting list.